Moreover, in the double-blind, placebo-controlled, phase 3 ATTR-ACT trial, the primary GPC analysis, prioritizing time to death followed by time to hospitalization, showed evidence of efficacy of tafamidis (n = 264) over placebo (n = 177) and lead to drug approval in transthyretin amyloid cardiomyopathy patients [27]. This evidence concerns the gene TTR and cardiac amyloidosis.